Exit071 is a company headquartered in the Netherlands.
Exit071 develops proprietary microfluidic technology for efficient isolation and molecular analysis of exosomes, enabling high-throughput biomarker discovery and accelerating drug development.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.